Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination bronchodilator therapy.

G M Shenfield

    Drugs
    |November 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Bronchodilator drug combinations, including anticholinergics and beta-adrenoceptor agonists, offer additive therapeutic benefits. While not synergistic, these combinations enhance bronchodilation, potentially with reduced side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The effect of different nebulizers with and without intermittent positive pressure breathing on the absorption and metabolism of salbutamol.

    British journal of clinical pharmacology·2012
    Same author

    The clinical pharmacology of salmefamol.

    British journal of clinical pharmacology·2012
    Same author

    The effect of prednisone treatment on the half-life of intravenous hydrocortisone.

    British journal of clinical pharmacology·2012
    Same author

    Absorption of drugs by the lung.

    British journal of clinical pharmacology·2012
    Same author

    Failure to weigh patients in hospital: a medication safety risk.

    Internal medicine journal·2007
    Same author

    The many essential interfaces of clinical pharmacology.

    Clinical and experimental pharmacology & physiology·2001
    Same journal

    Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

    Drugs·2026
    Same journal

    Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

    Drugs·2026
    Same journal

    Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

    Drugs·2026
    Same journal

    Relacorilant: First Approval.

    Drugs·2026
    Same journal

    Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

    Drugs·2026
    Same journal

    Linerixibat: First Approval.

    Drugs·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Respiratory Medicine

    Background:

    • Bronchodilators are crucial for managing respiratory diseases.
    • Three main classes exist: anticholinergics, beta-adrenoceptor agonists, and methylxanthines.
    • Theoretical basis for additive/synergistic interactions due to shared biochemical pathways.

    Purpose of the Study:

    • To review the evidence for interactions between different classes of bronchodilators.
    • To assess the therapeutic value and potential side effects of bronchodilator combinations.

    Main Methods:

    • Review of in vitro and in vivo studies on bronchodilator combinations.
    • Analysis of clinical data on interactions between anticholinergics, beta-adrenoceptor agonists, and methylxanthines.
    • Examination of drug administration routes and side effect profiles.

    Related Experiment Videos

    Main Results:

    • In vivo studies show additive, not synergistic, bronchodilator effects for most combinations.
    • Anticholinergics combined with beta 2-adrenoceptor agonists demonstrate additive bronchodilation, with inhaled beta 2-agonists preferred first.
    • Methylxanthines (theophylline) combined with selective beta 2-adrenoceptor agonists show additive effects, allowing for potential dose reduction and improved outcomes, especially with different administration routes.

    Conclusions:

    • Bronchodilator combinations, particularly anticholinergics with beta 2-agonists and methylxanthines with beta 2-agonists, provide therapeutic benefits through additive effects.
    • Fixed-dose combination bronchodilators are not recommended.
    • Further research is needed to fully elucidate the benefits and optimal use of bronchodilator combinations.